Brian J. Druker

Biography

  Dr. Brian J. Druker, M.D., serves as a Scientific Advisor of Xcovery LLC. Dr. Druker served as a Principal Scientific and Clinical Advisor of SGX Pharmaceuticals, Inc. He is a scientific founder of Blueprint Medicines Corporation. Dr. Druker also serves as Chairman of Leukemia Research of Oregon Health & Science University of Cancer Institute. He has been the Chairman of Scientific Advisory Board at Aptose Biosciences Inc., since October 29, 2013. He served as Chairman of Clinical Advisory Board of Avalon Pharmaceuticals, Inc. since January 2007. He serves as Member of Scientific Advisory Board at Third Coast Therapeutics, Inc. Dr. Druker served as a Member of the Clinical Advisory Board (CAB) of Avalon Pharmaceuticals, Inc., since January 2007. He serves as Member of the Scientific Advisory Board of Gilead Sciences Inc. He also serves as a Member of Scientific Advisory Board of GRAIL, Inc. and Blueprint Medicines Corporation. He has been a Scientific Co-Founder of MolecularMD Corp., since 2006 and serves as its Scientific Advisor. He serves as a Director of American Association For Cancer Research. He serves as a Member of Council of Scientific Advisors at The Translational Genomics Research Institute. He serves as a Member of the Advisory Group of OVP Venture Partners. Dr. Druker has been Member of Clinical Oncology Advisory Board at Ambit Biosciences Corporation since December 13, 2006. He has been Member of the Hematology and Oncology Clinical Advisory Board at Ambit Biosciences Corporation since February 28, 2008. He served as Member of Scientific Advisory Board at CTI BioPharma Corp. since October 14, 2013 until January 21, 2017. He served as Member of Scientific Advisory Board at Avalon Pharmaceuticals, Inc., Member of Scientific Advisory Board at Cylene Pharmaceuticals, Inc. and Aquinox Pharmaceuticals Inc. He is a Professor in Medicine of Leukemia Research of Oregon Health & Science University of Cancer Institute. He is a Howard Hughes Medical Institute Investigator of OHSU Cancer Institute, where he is professor of medicine in the Division of Hematology & Medical Oncology and has joint appointments in the Department of Cell and Developmental Biology and the Department of Biochemistry and Molecular Biology. Dr. Druker is director of the Knight Cancer Institute at Oregon Health & Science University, associate dean for oncology in the OHSU School of Medicine and JELD-WEN Chair of Leukemia Research at OHSU. Dr. Druker has received many awards for his work with Gleevec including the Robert-Koch Prize, the Medal of Honor from the American Cancer Society, the Richard and Hinda Rosenthal Award from the American Association of Cancer Research, the John J. Kenney Award from The Leukemia and Lymphoma Society, the Warren Alpert Foundation Prize from Harvard Medical School and the Pioneer of Survivorship Carpe Diem Award from the Lance Armstrong Foundation. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, the National Academy of Sciences in 2007 and the American Academy of Arts and Sciences in 2012. He is an internationally known researcher and recipient of the 2009 Lasker-DeBakey Award for Clinical Medical Research , ( often referred to as America's Nobel), the Japan Prize and top awards from the American Cancer Society, the Lance Armstrong Foundation, American Society of Hematology and the Leukemia and Lymphoma Society, among others. He holds the American Society of Hematology's Dameshek Prize and the David A. Karnofsky Award from the American Society of Clinical Oncology. He was associated with the Washington University School of Medicine in St. Louis. Dr. Druker is widely recognized for his seminal contributions to the discovery and development of Gleevec. His extensive research into the regulation of the growth of cancer cells led to the development of Gleevec, which is approved for the treatment of chronic myelogenous leukemia and GIST. He completed a fellowship in medical oncology at Harvard's Dana-Farber Cancer Institute. He completed his internship and residency in internal medicine at Barnes-Jewish Hospital. Dr. Druker received his BS degree in chemistry and his M.D. from the University of California, San Diego.

Research Interest

ONCOLOGY